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Introduction: α-Synuclein (α-syn) is a key protein in Parkinson’s disease (PD), and one of its phosphorylated forms,
pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally
collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300
subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2
mutation carriers).
Results: Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson’s Disease
Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease
progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated
with UPDRS scores at the baseline (R = −0.244, p = 0.017), but not final point, suggesting that this association may
depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of
LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and
disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129
levels correlated with worse clinical condition at early stages, but better condition at later stages.
Conclusion: The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD
progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD
experimentally.
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Parkinson’s disease (PD) is a common age-related neuro-
degenerative disease, with a complicated etiology featuring
both genetic and environmental components [1,2]. The
abundant, membrane-associated protein α-synuclein (α-
syn) is the primary component of Lewy bodies (LBs), a de-
fining feature of PD, although whether these inclusions
are themselves detrimental, or are a protective mechanism
for sequestering toxic soluble oligomeric forms of α-syn,
remains controversial [3,4].* Correspondence: zhangj@uw.edu
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unless otherwise stated.Posttranslational modifications of α-syn, particularly
phosphorylation at serine 129 (pS129), may be critical in
PD [5,6], as α-syn in LBs from patients with sporadic
[5-8] and genetic [9] forms of PD is overwhelmingly
phosphorylated at S129. Further, pS129 alters character-
istics of α-syn such as its propensity for aggregation
[6,10,11], toxicity [10-12], and protein associations [13,14].
However, considerable controversy exists over the effects
of pS129 on neurodegeneration in PD, with contradictory
findings in transgenic fly [10] and mammalian models
studying effects of phosphorylation on α-syn toxicity
[11,15] and neurodegeneration [16]. These contrasts sug-
gest that the effects of pS129 may be highly model-
dependent, making assessment of the natural course of
pS129 in human disease imperative for more accuratel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tional investigations.
Our recent study in a cross-sectional cohort found
that, unlike total α-syn, CSF pS129 is higher in PD than
healthy controls [17]. Remarkably, it also significantly
correlated with PD severity, suggesting that, in addition
to being mechanistically important in the pathology of
PD, pS129 may serve as a biomarker for PD progression.
However, this hypothesis must be interrogated in longi-
tudinally collected samples, particularly in subjects with-
out confounding factors presented by medication. Yet,
longitudinal studies of PD face a number of challenges,
including repeated collections of CSF over a prolonged
time, allowing enough time to detect biochemical alter-
ations in this slowly progressive disease.
We studied pS129 in the DATATOP (the deprenyl and
tocopherol antioxidative therapy of Parkinsonism) co-
hort, in which recently diagnosed PD patients (that is,
subjects with early, unmedicated clinical PD) underwent
repeated CSF sampling, two years apart. To extend our
findings to a wider range of disease stages, we further
examined CSF samples obtained from subjects with
LRRK2 mutations (which lead to late-onset PD similar
to the idiopathic disease), including patients at preclinical
stages [18,19], and results published previously [17,20]
from a large multi-center collaborative cohort including
subjects with later stage PD. With these cohorts, we iden-
tified a potential non-linear relationship between CSF
pS129 and disease severity.
Materials and methods
Study subjects
Cohorts used in this study were approved by the Institu-
tional Review Boards of all participating institutions.
Although cohorts were recruited and samples were
collected independently, similar protocols were used
throughout, including collection between 6 and 10 am,
freezing immediately after collection, use of polypropyl-
ene tubes, addition of protease inhibitor cocktail, and
thawing immediately prior to the assay. Samples were
centrifuged for 10 minutes at 15,000 rpm before all as-
says (α-syn, pS129, or hemoglobin). Two longitudinal
samples were collected from the DATATOP cohort sub-
jects, and one cross-sectional sample was collected from
each Multi-center collaborative cohort and LRRK2 co-
hort subject.
DATATOP cohort
Detailed description of the DATATOP cohort, recruited
in 1987, has been previously published, [21] as have the
additional criteria used in our analyses [20,22]. To elim-
inate potential confounding effects, only those assigned
to the placebo group were included in this study. Sub-
jects were followed for ~24 months, with the primaryoutcome of time to “endpoint,” defined as the develop-
ment of symptoms severe enough to require treatment
with levodopa, as determined by a blinded clinician.
Clinical data, such as Unified Parkinson’s Disease Rating
Scale (UPDRS) score, was evaluated approximately every
three months, and CSF was collected twice, once each at
the baseline and final time points. We included subjects
whose follow-up time was >6 months, resulting in a co-
hort of 95 PD patients.
Multi-center collaborative cohort
CSF samples were collected from a total of 209 PD pa-
tients, recruited at nine collaborative centers, using similar
collection and quality control protocols. Patients under-
went extensive clinical evaluation; a detailed description of
this cohort, including pS129 scores, has been previously
published [17]. Of note, the range of MMSE scores is
large, and some of our subjects, especially those enrolled
in Multicenter-collaborative cohort, have MMSE scores
meeting the criteria of cognitive impairment or even de-
mentia. However, as >75% typical PD patients show cogni-
tive dysfunction eventually [23,24], we did not exclude
these subjects, because it would be impossible to also ex-
clude the equivalent patients (that is, those who would
eventually become demented) from the cohorts with sub-
jects at earlier stages.
LRRK2 cohort
CSF samples from 23 asymptomatic and seven symp-
tomatic LRRK2 mutation carriers at early stages (sub-
jects with UPDRS > 20 were excluded to allow exclusive
focus on early PD) were assessed. Note that disease dur-
ation, used to define “early” PD in the other cohorts, is
not available, as most of these subjects have not yet been
diagnosed with PD. Further details concerning recruit-
ment, demographics, and other CSF markers in a subset
of this cohort have been previously published [18,19].
PET studies
Within one year of CSF sample collection, each LRRK2
cohort subject traveled to the Pacific Parkinson’s Research
Centre (Vancouver, BC, Canada) for positron emission
tomography (PET) scans. Any antiparkinsonian medica-
tions were stopped at least 12 h before assessment. Sub-
jects were scanned with 11C-(±)-α-dihydrotetrabenazine
(TBZ), a ligand of vesicular monoamine transporter 2, as
previously described [18,19]. All PET data were normal-
ized to age-matched control values. Because the asymp-
tomatic group included both subjects with marked
reductions in TBZ scores (likely at an early PD stage) and
subjects with normal TBZ scores (who may be truly un-
affected at the time of sampling), we limited some analyses
to subjects with age-normalized TBZ scores <1.0.
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CSF pS129 was measured according to our previously
published protocol [17]. Briefly, MicroPlex microspheres
(Luminex, Austin, TX, USA) were coupled with anti-α-
synuclein antibody (ASY-1 [25,26]). For each subject,
75 μl CSF was diluted with 25 μl assay diluent (0 · 1%
bovine serum albumin [Sigma, St Louis, MO] in PBS).
Analytes were detected using biotinylated anti-human
pS129 antibody [27] and streptavidin-R-PE (Prozyme,
Hayward, CA, USA). Plates were read on a LiquiChip
Luminex 200 Workstation (Qiagen, Valencia, CA, USA).
CSF α-syn was measured as previously described; [28]
results for the entire DATATOP cohort have been pub-
lished separately [20]. In all assays, samples were ran-
domly distributed across plates to avoid confounding
due to the plate location, and assay operators were blind
to the disease status or time point of samples.
Although frozen DATATOP CSF samples underwent
prolonged storage, concentrations of CSF markers (Aβ,
tau, α-syn), reported elsewhere [20,22], were comparable to
recently collected samples in our previous studies [28,29].
Hemoglobin measurements
Blood contamination was assessed using Human Hemo-
globin ELISA Quantitation Kit (Bethyl Lab Inc., Mont-
gomery, TX, USA) according to the manufacturer’s
instructions.
Statistical analysis
All analyses were performed using PASW Statistics 19
(IBM, Chicago, IL). Our α-syn and pS129 assays typically
result in inter-plate variability <15% and intra-plate vari-
ability <10% [17,28]; no corrections were made for as-
says that performed within this range. Within each
cohort, interassay variability was ensured by including
identical reference samples on each assay plate, and
inter-plate variability controlled by correcting for these
references. No corrections were made between cohorts.
Values are reported as mean ± standard deviation (SD)
unless otherwise noted. Change in biomarker levels was
analyzed using a paired t-test on the difference (final-
baseline) of CSF sample values following Shapiro-Wilk
test for normality. Because a previous study demon-
strated that blood contamination influences levels of
total α-syn [28], 25 subjects with at least 1 sample con-
taining >200 ng/ml hemoglobin, the level at which blood
α-syn confounds CSF α-syn levels, were excluded from
analysis comparing longitudinal changes in pS129, α-syn
or pS129/α-syn ratio. Associations between CSF levels
and UPDRS scores are reported as Pearson correlation.
Association with age-normalized TBZ scores is reported
as Spearman correlation, due to the highly non-normal
distribution of TBZ scores. Subjects diagnosed with PD
≤2 years before sample collection (the median diseaseduration for DATATOP subjects at baseline) were con-
sidered “early” stage cases for the purpose of segregation
of cohorts into “early” vs “late” PD.
Results
Demographic distribution of DATATOP cohort
Clinical evaluations and CSF were assessed in 95 subjects
assigned to the original DATATOP placebo group. Demo-
graphic characteristics, clinical scores, and CSF levels of
protein markers of all cohorts are presented in Table 1.
Endpoint, defined as development of symptoms of suffi-
cient severity to require administration of dopamine sup-
plementing drugs, was reached by 72 DATATOP subjects.
Longitudinal alteration of phosphorylated α-syn in CSF
We tested the change in pS129 and the pS129/α-syn
ratio over the two-year DATATOP follow-up period.
Despite a negative trend, suggesting a small decrease,
no significant difference was observed between baseline
and final total α-syn (mean difference −190.50 pg/ml,
95% CI −382.57, 1.56, p = 0.052), in subjects meeting Hgb
cutoff. In contrast, both pS129 and pS129/α-syn ratio in-
creased (5.60 pg/ml, 95% CI [−0.01, 11.21], p = 0.050 and
0.034; 95% CI [0.007, 0.061], p = 0.014, respectively). We
examined separately the subset of patients who reached
endpoint, and found that the differences between final
and baseline scores for pS129 and pS129/α-syn ratio were
somewhat larger, indicating that the changes are more
pronounced in the subset of subjects that progressed to
requiring levodopa therapy (Table 2; Figure 1). Examining
the relationship between total and phosphorylated α-syn,
we found that at baseline, pS129 was significantly cor-
related with α-syn (R = −0.420; p < 0.001), but not at the
final time point (R = −0.109; p = 0.335).
This finding of increasing pS129 is quite consistent
with previous studies; however, the DATATOP cohort
does not include neurologically normal control subjects
in which to examine age-related changes in CSF pS129,
so any changes due only to aging would not be detected
in this set. In order to approximate this measurement,
we studied the cross-sectional relationship between age
and pS129 at the baseline and final time points, and
found no correlation (p > 0.05; Pearson correlation), in
either the full cohort or only the subset that reached
endpoint. In contrast to a previous study [28], there was
no significant correlation between age and total α-syn at
baseline (R = 0.176; p = 0.107); however, a significant cor-
relation was observed between age and total α-syn at the
final time point (R = 0.267; p = 0.017).
CSF pS129 and disease severity in cohorts at differing
stages of disease progression
Having observed a longitudinal increase in pS129 in re-
cently diagnosed PD patients, we next sought to examine









Age, y (mean ± SD) 61.08 ± 8.91 63.08 ± 8.68 65.94 ± 10.54 53.13 ± 13.88
Sex F/M (% Male) 35/60 (63%) 35/60 (63%) 52/157 (75%) 15/15 (50%)
Duration of disease, y
Mean ± SD 1.9 ± 1.41 4.02 ± 1.55 7.9 ± 6.48 –
Range 0 – 6 1 – 9 0 – 42
MMSE
Mean ± SD 28.85 ± 1.57 28.81 ± 1.48 28.47 ± 3.07 –
Range 23 – 30 22 – 30 11 – 30
H&Y†
Median 2.0 2.0 2.0 –
Range 1.0 – 2.5 1.0 – 4.0 0.0 – 5.0
UPDRS‡ Total
Mean ± SD 24.87 ± 12.50 40.73 ± 16.63 – –
Range 0 – 61 9 – 88
UPDRS Motor
Mean ± SD 16.90 ± 9.52 27.36 ± 12.13 23.72 ± 11.87 5.20 ± 4.73
Range 0 – 50 5 – 62 0 – 71 0 – 20
Ps129 (pg/ml)
Mean ± SD 114.66 ± 17.14 117.89 ± 17.92 74.01 ± 26.67 63.79 ± 22.73
Range 57.11 – 151.63 68.66 – 170.78 0.00 – 203.17 35.2 – 145.1
Total α-syn (pg/ml)
Mean ± SD 630.83 ± 703.08 639.48 ± 677.95 553.61 ± 409.22 744.78 ± 1169.94
Range 186.3 – 6343.5 173.6 – 4523.0 140.0 – 2990.0 170.98 – 5735.08
Ratio
Mean ± SD 0.2530 ± 0.1232 0.2688 ± 0.1433 0.177 ± 0.098 0.172 ± 0.132
Range 0.01 – 0.77 0.02 – 0.86 0.00 – 0.53 0.01 – 0.56
†Hoehn and Yahr.
‡Unified Parkinson’s Disease Rating Scale3.
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across a wider range of PD stages than has previously been
examined, by studying early clinical PD in recently diag-
nosed subjects (DATATOP), moderate to severe clinical
PD (multi-center collaborative cohort) and very early/pre-
clinical PD (LRRK2 cohort).Table 2 Paired t-test, change in marker: (Hgb > 200 excluded
identical subject groups
Subjects reaching endpoint (N = 51) Subjects not r
Mean ST dev Sig Mean
Ps129 (pg/ml) 8.73 24.43 0.014 −2.78
Ps129/Syn 0.040 0.123 0.024 0.018
Syn (pg/ml) −169.93 877.37 0.173 −245.73
Bold font indicates significance at the p=0.05 level.DATATOP cohort: early clinical PD
We examined the relationship of CSF pS129 with PD se-
verity. A negative correlation was observed between
pS129 and UPDRS motor scores at baseline (R = −0.244,
p = 0.017), but not at the final time point (Table 3), after
approximately two years of disease progression, whenfor both α-syn and pS129 to allow direct comparison of
eaching endpoint (N = 19) All subjects w/Hgb ≤ 200 (N = 70)
ST dev Sig Mean ST dev Sig
19.09 0.534 5.60 23.53 0.050
0.079 0.347 0.034 0.113 0.014
134.65 0.085 −190.50 805.51 0.052
Figure 1 Longitudinal changes in pS129 and relationship with total α-syn. A) Change in pS129 by baseline level. Triangles: subjects that did
not reach endpoint. Squares: subjects that reached endpoint. Solid line: regression line generated from all subjects combined. B) Association
between total α-syn and pS129 levels by time point. Circles: baseline time point. Squares: final time point. Lines represent correlation between
total α-syn and pS129 for each time point.
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ratio was not correlated with UPDRS scores at any time
point. Controlling for age and gender did not signifi-
cantly alter the results in any case (not shown).
The cross-sectional correlation with UPDRS (lower in
subjects with worse UPDRS scores at baseline) and the
longitudinal change in pS129 levels (increasing with
progression of disease severity) appear contradictory.
Additionally, the DATATOP baseline correlation results
seemed to conflict with our previous study [17], in
which pS129 was significantly positively correlated with
UPDRS motor score in a large cohort. This apparent
paradox could be explained if the negative correlation is
unique to the baseline DATATOP cohort, rather than a
feature of PD progression; however, we wished to inves-
tigate whether it might be a feature of a multi-stage re-
sponse, reflecting a non-linear (U-shaped) time course
of pS129 expression. Because a second, comparable lon-
gitudinal cohort was not available to study this question,
we instead examined two additional cross-sectional co-
horts, one with more advanced PD subjects [17] and one
with preclinical/very early PD subjects [18,19], to at-
tempt to estimate the course of CSF pS129 over a longer
period of PD progression.Table 3 Comparison of correlation between UPDRS motor scor
duration
DATATOP baseline DATATO
N Corr P N Cor
pS129
Whole cohort 95 −0.244 0.017 95 0.14
Disease duration ≤2 years 69 −0.289 0.016 18 −0.
Disease duration >2 years 23 −0.067 0.778 74 −0.
B: baseline time point. F: final time point. Most LRRK2 cohort subjects have not yet
and 3 multi-center collaborative cohort subjects.
Bold font indicates significance at the p=0.05 level.Comparison of DATATOP and multi-center collaborative
cohorts: early vs moderate/severe clinical PD
To determine whether the difference in the direction of
correlation between CSF pS129 and UPDRS motor
scores in DATATOP and our previous multi-center col-
laborative cohort could be explained by the much earlier
disease status of the DATATOP cohort, we re-analyzed
both cohorts after stratifying by disease stage (Table 3;
Figure 2 B-E), defining subjects with a disease duration
less than or equal to the median for the baseline DATA-
TOP cohort (2 years) as having early stage PD. In the
DATATOP cohort, the significant negative correlation
between UPDRS and pS129 was observed in the early
stage subjects at the baseline time point (disease dur-
ation ≤ 2 years; n = 69), but not in the smaller group with
early PD at the final time point (n = 18). No significant
trend was observed at either time point in the subset
with more advanced PD (disease duration >2 years; n =
23 and 74 for baseline and final, respectively). Next, we
stratified the multi-center collaborative cohort using the
same criteria, although this group included many more
subjects with longer disease durations. The trend of in-
creasing UPDRS motor scores with higher pS129 CSF
values was significant in both the whole group (n = 199)es and CSF pS129 levels, overall and stratified by disease
P final Multi-center collaborative LRRK2
r P N Corr P N Corr P
7 0.834 199 0.147 0.038 30 −0.050 0.794
093 0.712 32 0.043 0.817 –
050 0.674 164 0.173 0.027 –
received PD diagnoses. Disease durations not available for 3 DATATOP subjects
Figure 2 The relationship between pS129 and motor symptoms changes with disease severity. pS129 and UPDRS motor scores by disease
duration A) Relationship between CSF pS129 and UPDRS motor scores in subjects in DATATOP and cross-sectional cohorts. Line is Loess curve for
combined datasets including multi-center collaborative cohort and DATATOP baseline and final time points. B)-E) Relationship between pS129
and UPDRS in cohort subsets divided by disease stage. B) DATATOP DD less than 2 years. C) DATATOP DD greater than 2 years. D) Cross-sectional DD
less than 2 years. D) Cross-sectional DD greater than 2 years. MC: Multi-center collaborative cohort. DD: Disease duration, time since diagnosis in years.
DB: DATATOP baseline time point. DF: DATATOP final time point. Diamonds: multi-center collaborative cohort. Black circles: DATATOP baseline. Gray
circles: DATATOP final.
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earlier stage PD. When the DATATOP baseline and final
time point data (early PD) were analyzed together with
the multi-center cross-sectional data (moderate to late
PD), a U-shaped relationship between CSF pS129 and
UPDRS motor scores appeared, i.e., a negative associ-
ation during early PD (higher pS129 was associated with
lower UPDRS and lesser disease severity), followed by an
increasingly positive association with progressing disease
(Figure 2A). Therefore, this data supports the idea that
the direction of the association between pS129 and
UPDRS is non-linear and dependent on disease stage,
and there may be a transition between negative and
positive correlation between CSF pS129 and disease se-
verity, leading to a U-shaped curve over long periods of
follow-up or a wide range of severities included in a
cross-sectional study.
LRRK2 cohort: very early and preclinical PD
If the hypothesis that the correlation between CSF
pS129 and disease severity is dependent on PD progres-
sion is true, then it would be expected that subjects with
very early or preclinical PD would show a negative cor-
relation (similar to DATATOP baseline). However, pre-
clinical/very early PD patients have very low (or 0)UPDRS scores, making analysis of the correlation diffi-
cult. Therefore, we sought to test this hypothesis using a
cohort of LRRK2 mutation carriers, in which preclinical
PD signs were assessed by neuroimaging (Table 1). As
expected, no correlation was observed between pS129
and UPDRS (Table 3) in this small cohort of mostly clin-
ically asymptomatic subjects, as the UPDRS values for
asymptomatic subjects were near or equal to 0. However,
LRRK2 subjects underwent PET imaging, and those with
clinical PD show markedly reduced age-normalized TBZ
scores (Figure 3A); therefore, TBZ scores, which appear
to undergo changes at an earlier stage than UPDRS,
were used to measure severity of the pathology in these
subjects. In LRRK2 mutation carriers, a trend of decreased
pS129 with greater disease severity was observed, and was
significant in the subset of subjects with early PD path-
ology, indicated by TBZ < 1 (n = 20, Spearman’s rho 0.456,
p = 0.043; Figure 3B). This result is consistent with the
trend seen in early PD cases of DATATOP cohort, i.e.
higher ps129 values were associated with higher TBZ
scores and lesser disease severity (note that high TBZ
scores and low UPDRS scores both reflect milder disease),
suggesting that the finding of a negative relationship at
early disease stages is not unique to the DATATOP
cohort.
Figure 3 LRRK2 subjects with greater brain pathology have lower CSF pS129. A) Significant decrease in TBZ scores in subjects with PD
diagnoses. B. Relationship between TBZ scores and pS129 in LRRK2 mutation carriers. Note that x-axis is inverted to facilitate comparison with
UPDRS measurements in Figure 2. Dotted regression lines represent whole cohort; solid lines represent cohort excluding subjects with TBZ scores
≥1. Black triangles: Subjects without PD diagnosis and TBZ < 1. Open triangles: Subjects with no diagnosis and TBZ > 1. Circles: Subjects with PD
diagnosis and UPDRS motor scores < 20.
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Several key findings are presented in this study: 1) pS129
and pS129/α-syn ratio increased in longitudinally col-
lected CSF from untreated early PD patients, particularly
those who progressed to requiring dopamine therapy;
and 2) the relationship between pS129 and PD severity
differed at earlier and later disease stages (high pS129
reflected less severe symptoms at earlier stages, but not
at later stages). We examined this possibility using re-
analysis of a previously studied cohort, after stratification
by disease duration, and found that this progression ap-
peared as a U-shaped curve when the two cohorts were
combined. Moreover, this interpretation was supportedby examination of a cohort of LRRK2 carriers with early
or preclinical PD.
Longitudinal changes in pS129 in PD progressions
α-Syn in LBs is highly phosphorylated at S129 [5,6,10],
particularly in more severe stages of Lewy pathology
[7,20], suggesting a progressive increase in pS129 as PD
advances. Additionally, cross-sectional studies in brain
tissue and CSF indicate increased phosphorylated α-syn
in PD [6,17], suggesting that it may be useful as a PD
biomarker. However, whether it increases longitudinally
in the CSF of individual subjects has been less well ex-
amined. Here, we found that pS129 increased over the
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though it trended to be lower in more advanced stages,
did not achieve statistical significance in the placebo
group. The ratio of pS129/α-syn showed a greater in-
crease, as anticipated given their opposite expected
directions of change. This investigation is, to our know-
ledge, the first study of pS129 in living subjects with
CSF collected longitudinally over a reasonably long
period of time (about two years). The observation is en-
tirely consistent with our previous cross-sectional study
demonstrating that pS129 and the pS129/syn were
higher in PD than in controls, and pS129 significantly
positively correlated with severity of motor symptoms
[17]. Our data, however, contrasted with another recent
study of post-mortem ventricular fluid, which observed
no difference in pS129 between PD patients and controls
[30]. The lack of significance between advanced PD and
controls, when assessed using ventricular fluids collected
at autopsy, could be attributed to a number of factors,
including cohort size, antibodies used, or use of autopsy
ventricular fluid, which has a different protein compos-
ition from lumbar CSF [31]. However, later studies by
the same group found increased plasma pS129 in PD,
but no longitudinal increase in follow-up periods be-
tween 3 months and up to 4 years [32,33]. In light of
our CSF results, the lack of further increase in plasma
pS129 in longitudinal samples could be explained by a
combination of different sample types, as well as by the
follow-up period, particularly considering the modest
magnitude of the change observed in CSF here, even
over approximately two years. Based on our CSF investi-
gations, it is likely that a much longer period of follow-
up is needed to detect biochemical alterations in slow
neurodegenerative processes [20,22].
pS129 and disease severity: evidence for a non-linear
pattern in PD progression?
The most intriguing observation in the current study is
that pS129 negatively correlated with PD severity at
baseline, i.e. at a relatively early stage of the disease, in
the DATATOP cohort. We hypothesized that this para-
doxical observation might depend on disease stage, and
separation of two cohorts by stage showed a trend, in
both cohorts, toward more positive correlation with in-
creasing severity. The effect of this change would be
reflected in clinical trials as contradictory associations
between early and late cohorts, as was observed when
comparing the baseline DATATOP and multi-center col-
laborative cohorts. We considered that this relationship
could be explained if pS129 decreases in the initial or
preclinical stages of PD (leading to the negative correl-
ation at early but post-diagnosis time points such as
DATATOP baseline), then progressively increases at
later stages (leading first to a loss of any correlation,followed by the introduction of a positive correlation, as
well as longitudinally observed increase in concentra-
tion). We therefore sought to determine if a non-linear
relationship appeared when a wider range of disease
stages are studied together, particularly by including sub-
jects at very early stages. Remarkably, the trend of a
negative correlation between pS129 and PD severity at
early stages was maintained in a cohort consisting of
LRRK2 mutation carriers exhibiting early signs of PD.
Although UPDRS scores were typically very low in these
subjects, TBZ imaging, which reflects nigrostriatal dam-
age robustly [34], showed that higher pS129 levels were
associated with better disease states.
Of four groups (DATATOP baseline and final, multi-
center collaborative, and LRRK2), only the DATATOP
final cohort, at intermediate disease stage, showed no as-
sociation between pS129 and UPDRS, in contrast to the
late multi-center collaborative cohort, where a clear
positive correlation is shown. This lack of correlation in
a portion of DATATOP cohort may be explained by a
mixture of the limited number of the early stage subjects
at the final time point and the comparatively earlier sta-
tus of even the “late” subjects, most of which just
reached the point of requiring PD medication. This leads
to the hypothesis that these subjects are at the stages
where the pS129/severity relationship is undergoing a
negative-to-positive transition (i.e., near the vertex of a
U-shaped curve). It should also be noted that, although
the reported severity (UPDRS scores) in the multi-center
collaborative cohort overlapped substantially with that of
the DATATOP final group, in the former, all subjects
were on anti-parkinsonism medications, partially mask-
ing the true severity of their symptoms. In other words,
subjects in this cohort can be considered to have more
severe PD than DATATOP subjects with equivalent
scores. For the reasons discussed above, it is not surpris-
ing that neither the levels of the markers at baseline, nor
their changes over the duration of the study, predicted
longitudinal progression in UPDRS of the DATATOP
cohort (data not shown).
Taken together, these data suggest the possibility that
the relationship between pS129 and disease severity may
alter with progression. The mechanisms by which such a
phenomenon occurs, and what it means for the role of
pS129 in PD pathogenesis, remain to be examined. One
possible interpretation of the current study is that phos-
phorylation increases as a compensatory mechanism,
explaining both its increasing levels and apparently
contradictory association with less severe symptoms at
early-mid stages, but that the benefits are eventually
overcome by accumulating negative effects of this or
other PD-related changes, explaining how pS129 could
continue to increase, and become associated with worse
outcomes in patients with more advanced disease.
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observations might provide some insight to the conflict-
ing results obtained in various animal models of PD. For
example, experiments in fly [10] and rat models [11,15]
found opposite effects of phosphomimetic mutant α-syn
on neuronal degeneration, and differing effects of phos-
phorylation on the propensity of α-syn to form aggre-
gates have also been reported [6,10,11,16,35]. Further,
differences have been observed between the phosphomi-
metic and genuine phosphorylated proteins [16,35],
complicating interpretation of these studies. If alter-
ations in pS129 depend on the stage of the disease, it is
likely that other disease-related molecular interactions
influence the effects of pS129 in the cell, and, for future
studies, the effects of pS129 must be investigated in
model systems that recapitulate the human condition as
closely as possible. An important caveat that must be
considered is that, while patients in the early/preclinical
cohorts (DATATOP and LRRK2) were untreated, those
in the multi-center collaborative cohort, in addition to
being at more advanced stages, are also undergoing
therapeutic treatment. With these datasets, one could
argue that the differing relationship between disease se-
verity and pS129 with progression is driven by effects of
drug treatments (for example, treatment could result in
increased pS129 levels, such that those with worse
symptoms requiring increased therapy exhibit the high-
est levels, and masking a negative relationship such as
was observed in both the DATATOP and LRRK2 co-
horts). While this remains a theoretical possibility, the
fact that a further increase in pS129 occurred in the lon-
gitudinal DATATOP cohort (Table 2), where all subjects
are unmedicated, indicates PD therapy is unlikely the
primary cause of this observation.
Additional considerations
Several additional caveats must also be considered. One
obvious concern is the lack of neurologically normal
controls in the DATATOP study, meaning that no group
exists for comparison of PD-related changes in pS129
with its natural course with aging. Therefore, whether the
increasing levels of pS129 observed in the DATATOP co-
hort are due to PD progression or aging cannot be defini-
tively determined by this dataset alone. However, some
data exists to suggest that aging is not the primary factor.
First, we previously examined this question in our multi-
center collaborative cohort, and found no relationship
between age and pS129 in older PD patients or control
subjects [31]. Further, we examined the cross-sectional re-
lationship between pS129 and age in the DATATOP co-
hort, and again found no association. Together, these data
suggest that CSF pS129 is not dependent on age in the
older patients included here. However, this must be con-
firmed in longitudinally collected control subjects in laterstudies. Additionally, when using UPDRS to assess the
utility of CSF pS129 and/or pS129/α-syn in monitoring
the central nervous systems of PD patients, it is important
to consider that biochemical and clinical measures of dis-
ease reflect different things: CSF α-syn and pS129 are
measures of brain-wide pathology while UPDRS motor
score reflects largely the degeneration of nigrostriatal sys-
tem. Despite these caveats, sensitive and objective detec-
tion of alterations in CSF pS129 and total α-syn, which
both alter over two years of progression, [20] would
greatly aid clinical trials of novel, disease-modifying treat-
ments targeting α-syn-related systems.
In summary, in this study of pS129 using longitudinal
samples in addition to two cross-sectional cohorts, we
provide evidence for pathological alterations of pS129,
along with total α-syn, in the natural course of PD pro-
gression. These observations, though obtained in a large
cohort, need to be further validated in an independent
investigation, e.g. in prospective studies like the ongoing
Parkinson’s Progression Markers Initiative. The signifi-
cance of this study also goes beyond a biomarker re-
search, informing future mechanistic studies of the
disease, which should consider this natural course of
pS129 in humans when modeling PD experimentally.Compliance with ethical standards
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